RNA Sequencing at Mayo: A Powerful Clinical Tool for the Detection of Gene Fusions and Other Genetic Alterations in Tumors

Expires May 30, 2021

Presentation

 
Video length: 38 minutes

In this month’s “Virtual Lecture,” Kevin Halling, M.D., Ph.D., will review basic cancer genetics concepts and discuss examples of how RNA sequencing can be used to detect clinically relevant alterations in tumors such as gene fusions, point mutations, tumor mutation burden, and gene expression of individual genes or sets of genes.
 

Objectives

Upon completion of this program, participants should be able to:

  • Summarize the basic principles of cancer genetics.
  • Discuss clinical applications of RNA-sequence testing for the management of oncology patients.
  • Predict the ability of RNA sequencing to identify different types of genetic alterations, such as chromosomal rearrangements, point mutations, copy number alterations, and tumor mutation burden, that are observed in tumors.

 

Intended Audience

This program is appropriate for clinicians, pathologists, medical technologists, nurses, pharmacists, and other allied health staff.
 

Faculty

Photo of Kevin Halling, M.D., Ph.D.Kevin Halling, M.D., Ph.D.
Professor of Laboratory Medicine and Pathology
Division of Laboratory Genetics and Genomics
Mayo Clinic, Rochester, Minnesota
 
 

 

 

Level of instruction

Intermediate
 

Credit

The following types of credit are offered for this program:
ASCLS P.A.C.E.®

To obtain credit:

  1. Watch the video.
  2. Complete the posttest and evaluation that launches immediately following the video.
  3. Generate and print your certificate(s).

 

ASCLS P.A.C.E.®

Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of .5 P.A.C.E.® contact hour.

mmledu

MCL Education

This post was developed by our Education and Technical Publications Team.